(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 183.42% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Taysha Gene Therapies's revenue in 2026 is $5,485,000.On average, 14 Wall Street analysts forecast TSHA's revenue for 2026 to be $581,612,878, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $5,131,878,334. On average, 13 Wall Street analysts forecast TSHA's revenue for 2027 to be $7,981,618,518, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $33,495,688,426.
In 2028, TSHA is forecast to generate $48,102,806,248 in revenue, with the lowest revenue forecast at $29,824,196,041 and the highest revenue forecast at $97,173,338,125.